Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 19, 2015European Journal Of Haematology

Direct‐acting oral anticoagulants: pharmacology, indications, management, and future perspectives

View Full Paper
Ask AI
Bookmark
Share

Population

Patients requiring prophylaxis and treatment of venous and arterial thromboembolism

Comparison

Direct-acting oral anticoagulants including… vs Vitamin K antagonists and heparins

Design

Review

Authors

AGAntonio Gómez‐OutesEuropean Medicines AgencyMSMa Luisa Suárez‐GeaAgencia Española de Medicamentos y Productos SanitariosRLRamón LecumberriClinica Universidad de Navarra

Discussion

Loading...

Member takes

Overview

Renal monitoring required with DOACs; review leaves open need for antidotes and outcome trials.

Structured PICO

P
Population
Patients requiring prophylaxis and treatment of venous and arterial thromboembolism
I
Intervention
Direct-acting oral anticoagulants (DOACs) including dabigatran, rivaroxaban, apixaban, and edoxaban
C
Comparator
Vitamin K antagonists and heparins

This review summarizes the pharmacology, efficacy, safety, and practical management of direct-acting oral anticoagulants for venous and arterial thromboembolism.

Cite This Study

Gómez‐Outes et al. (2015) studied this question.

synapsesocial.com/papers/6a824bbd32af6e78ca8776e4https://doi.org/10.1111/ejh.12610
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1New oral anticoagulant agents – general features and outcomes in subsets of patients2014 · 64 citations
  2. 2Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review2014 · 33 citations
  3. 3Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism2012 · 2,373 citations
  4. 4Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis2015 · 325 citations
  5. 5Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation2011 · 9,485 citations